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Abstract 
HIV-1 positive individuals demonstrate a wide variety of comorbidities based on their genetic 
makeup and their behavioral factors. Differentiation of gene expression caused by behavioral 
factors such as smoking of tobacco, consumption of alcohol and illicit drug use have been shown 
to occur through miRNA and can have additive and adverse effects on the co-morbidities 
associated with HIV-1 infection. Here, we proposed to identify the miRNA that are being 
differentially regulated by the above mentioned behavioral exposures and their possible effects 
on the progression to HIV-1 associated neurocognitive disorder (HAND) by performing a cross 
sectional study.  
The Multi-center AIDS Cohort Study (MACS) provided information on all the subjects 
used in this study. The samples collected were divided into study groups based on their infection 
and cognitive status, resulting in three categories, uninfected controls, HIV-1 positive/dementia 
negative and HIV-1 positive/ dementia positive. The term dementia was used to identify an 
individual with any neurocognitive impairment regardless of the actual impairment. The 
individuals in each category were further divided based on their behavioral habits, smokers, non-
smokers etc.  The miRNA was obtained from PBMCs of the selected individuals and quantified 
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using TaqMan real time PCR assays. Computational analysis was used to find the miRNA that 
was significantly regulated by performing inter and intra comparisons within the established 
categories.   
Comparison of miRNA’s in controls vs. HIV-1 positive/dementia negative subjects 
resulted in a majority of miRNA’s being up-regulated in all variables (smoking, alcohol 
consumption and pot use). Whereas, comparison of miRNA’s in controls versus HIV-1 
positive/dementia positive and HIV-1 positive/dementia negative vs. HIV-1 positive/dementia 
positive subjects resulted in a majority of miRNA’s being down-regulated in all variables. This 
anomaly shows that there is an association between HAND and miRNA expression, mostly by 
down-regulation. 
     Public Health Significance: The major public health significance projected to come from 
this study include the possible identification of patients who are prone to develop cognitive 
disorders and identification of mechanism(s) underlying the development of HAND, which may 
lead to identification of new drug targets. In the long term, this knowledge may yield novel 
therapeutic interventions for the treatment of cognitive disorders and antivirals targeting CNS 
compartments. 
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1.0  INTRODUCTION 
There are approximately 35.0 million people living with HIV-1 infection globally (WHO, 
HIV/AIDS key facts). In the era of antiretroviral therapy prevalence of HIV-1 has been steadily 
increasing, though incidence has decreased from 3.3 million in 2002 to 2.3 million in 2012 
(Maartens, Celum, & Lewin, 2014). As the population of HIV-1 positive individual’s ages, we 
now see an increase in HIV-1 associated co-morbidities, such as HIV-1 associated 
neurocognitive disorder (HAND) (Hellmuth, Milanini, & Valcour, 2014). Highly active 
antiretroviral therapy (HAART) has greatly reduced the morbidity and mortality of HIV-1 
infection, but high rates of HIV-1 associated neurocognitive disorders (HAND) continue to rise. 
What is more, HIV-1 positive individuals, who have received antiretroviral therapy, are still 
more prone to develop neurologic diseases and at a younger age then uninfected individuals 
(Chen, Gill, & Kolson, 2014). 
HAND is observed in 30-60% of all identified HIV-1 positive individuals; though it does 
present in a milder form than in the pre-HAART era, it still disrupts an individual’s quality of 
life (Lindl, Marks, Kolson, & Jordan-Sciutto, 2010). Behavioral habits, such as smoking of 
tobacco, consumption of alcohol and illicit drug use, have all been shown to have adverse health 
effects. Coupling these behavioral factors with HIV-1 infection has been shown to have an 
additive effect that adversely impacts neurocognitive functioning (Martin-Thormeyer & Paul, 
2009). Literature on both HIV-1 and stimulant useage indicates that along with host genetic 
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variants in immunologic genes affect an individual’s risk for neurocognitive impairments. These 
effects may occur at the transcriptional level by regulation of microRNA (need to find the 
source) 
MicroRNAs (miRNA) are small non-coding RNA molecules that regulate translation, 
stabilization and degradation of messenger RNA at the posttranscriptional level. MicroRNAs 
have been indicated to have a roll in various normal cellular functions; therefore disruption of 
their expression can lead to pathological conditions. It has been shown that a single miRNA can 
control several genes, which in turn regulate numerous signaling pathways. This is one of the 
reasons that miRNAs are thought to make good biomarkers to indicate a diseased state (Rico-
Rosillo, Vega-Robledo, & Oliva-Rico, 2014) 
HIV-associated comorbidities such as HAND can be aggravated by an individual’s 
behavioral habits. We believe that habits such as smoking, drinking, and illicit drug use may be 
affecting the individuals on a genetic level, which is they are affecting regulation of host cellular 
genes at the post-transcriptional level  through miRNA’s. If we identify the miRNA’s being 
regulated and understand the pathways being regulated we may be able to use the miRNA’s as 
potential biomarkers for HAND.  
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2.0  BACKGROUND 
2.1 HIV DISEASE PROGRESSION AND ASSOCIATED CO-MORBIDITIES 
2.1.1 Epidemiology of HIV-1 Infection 
Human immunodeficiency virus-1, which causes Acquired immunodeficiency syndrome (AIDS) 
was first reported in the United States in 1981(Gottlieb et al., 1981), and since then has been 
responsible for nearly 75 million infections (UNAIDS, 2013). Today despite our vast knowledge 
of inter species cross-transmission of simian immunodeficiency virus (SIV); known to be the 
virus from which HIV-1 originated; to humans from primates we are still unable to fully 
understand the complexity that is HIV-1 and how it continually exists as a global epidemic (Faria 
et al., 2014). Currently there are approximately 35.0 million individuals living with HIV in the 
world, with only 12.9 million people receiving antiretroviral therapy (ART) globally (WHO, 
2014). 
HIV-1 causes AIDS by attacking the immune system by primarily infecting two types of 
cells, the CD4+ T cells and the macrophages. Disease progression with HIV-1 infection is 
usually determined by loss of  CD4+ T lymphocytes (Post, Wood, & Maartens, 1996). HIV-1 
infection can be categorized into stages based on the CD4 count, as viral load increases the CD4 
count decreases until a viral set point is reached. After this point virus stabilization or viral set 
point occurs where the virus load levels off and the CD4 count increases slightly (Mehandru et 
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al., 2004). The next stage of HIV-1 infection usually lasts an average of ten years and is 
characterized as clinical latency, because though the virus is still active, very low levels of viral 
replication occur. At this stage an individual may exhibit healthy CD4 counts as well as 
undetectable amounts of virus (Wannamethee et al., 1998). The final stage of HIV-1 infection is 
termed AIDS and is represented by a CD4 count of less than 200 cells per cubic millimeter of 
blood. At this point the average survival is three years without treatment (Fevrier, Dorgham, & 
Rebollo, 2011). It is during this stage that co-infections termed opportunistic infections are more 
prevalent and most likely to be the cause of death. 
2.1.2 Types of HIV 
There are two types of human immunodeficiency viruses, HIV-1 and HIV-2, that cause acquired 
immunodeficiency syndrome, both of which originated in West Africa (Sharp & Hahn, 
2011).HIV-1 infection in humans was caused by four cross-species transmissions of simian 
immunodeficiency viruses (SIVs) from various primates, whereas, HIV-2 virus is due to eight 
independent transmissions of SIVs; only one of these transmission, the HIV-1 group M from 
chimpanzees in southeastern Cameroon, resulted in the global epidemic we see today (Peeters, 
Jung, & Ayouba, 2013). The virus that causes HIV-2 appears to be confined mostly to the West 
African countries (Cohen, 2000), HIV-1 on the other hand is seen in almost every country. 
Whereas, SIVs most closely related to HIV-1, have been shown to cause CD4 T-cell depletion 
and increased mortality in wild chimpanzees, suggesting that evolutionarily, some form of 
acquired immunodeficiency syndrome originated long before HIV-1 crossed species (Sharp & 
Hahn, 2010). 
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2.1.3 Mode of Infection 
HIV-1 spreads through direct contact of bodily fluids from someone with HIV. The main spread 
of the disease in the United States is through sexual contact or sharing infected needles (CDC, 
2014). In many other countries HIV-1 is transmitted through blood transfusion (Lackritz, 1998). 
HIV can also be transferred vertically from infected mother to child during pregnancy, childbirth 
or breastfeeding (Nadal, Arlettaz, & Berger, 2014). 
HIV-1 can infect various cells in the host, but it primarily infects two types of cells, CD4 
T-cells and macrophages. After a CD4 cell is infected with HIV, the virus goes through multiple 
steps to reproduce itself and create many more virus particles (Kedzierska & Crowe, 2002) 
Cell to cell transmission of HIV enables it to escape elimination by the immune system, 
by infecting cells that are not easily infected (Costiniuk & Jenabian, 2014). Cell to cell 
transmission is where the virus exploits and manipulates cell to cell contact which leads to 
increased spread and higher viral load in less time (Mothes, Sherer, Jin, & Zhong, 2010). Certain 
HIV-1 lineages are better adapted to enter cells that express low levels of CD4 such as cells in 
the CNS, and maintain sustained replication, which is associated with severe neurocognitive 
impairment (Joseph, Arrildt, Sturdevant, & Swanstrom, 2014). 
2.1.4 Co-morbidities and Risk Factors Associated with HIV-1 
HIV-1 infection can lead to an individual to become more susceptible to various other co-
infections and co-morbidities, especially during the later stage defined as AIDS. Individuals with 
weakened immune systems, such as those with AIDS are prone to develop illness from co-
infections called opportunistic infections which are infections caused by various pathogens that 
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do not usually cause illness in individuals with a healthy immune system. Some of the most 
common co-infections are candidiasis, which manifests as oral thrush, hepatitis, encephalopathy, 
herpes simplex and pneumonia (AIDS.gov, 2014). 
There are several other co-morbidities associated with HIV-1 infection  that are 
aggravated by the virus and therefore cause a more devastating outcome in those with HIV-1 
when compared to those who do not have HIV-1. For example it has been shown that there is a 
greater risk of cardiovascular disease in HIV-1 positive individuals than in the general 
population (Tripathi et al., 2014). One of the least understood and therefore hardest to treat co-
morbidities associated with HIV-1 infection is HIV-1-associated neurocognitive disorder or 
HAND.  
The term HAND was coined by the National Institute of Mental Health in 2007, and it 
encompasses the entire spectrum of neurological disease associated with HIV infection except 
delirium. A few of the more commonly seen manifestations of HAND are asymptomatic 
neurocognitive impairment ( ANI), minor neurocognitive disorder (MND) and HIV-associated 
dementia (HAD) (Rosca, Rosca, Simu, & Chirileanu, 2012).  HAND occurs quite early in the 
timeline of HIV infection, it has most likely taken root before an individual has even started on 
an antiretroviral regime. Early signs of HAND include memory loss and decreased 
concentration, which are mistakenly associated with age as opposed to HIV-1 infection (Eggers 
& fur die Deutsche Neuro, 2014). Recently, due to advanced antiretroviral therapy started as 
soon as an individual has tested positive, there has been a decrease in the incidence of HAND, 
but as the population of HIV positive individual’s ages the prevalence of HAND increases 
(Ances & Ellis, 2007).   
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MRI scanning of HIV-1 positive individuals using HAART, who have a history of 
substance abuse (alcohol, tobacco, etc.) shows increased degradation of the brain tissue, which 
can lead to HAND (Holt, Kraft-Terry, & Chang, 2012). 
2.2 EPIGENETIC EXPLANATION FOR HIV-ASSOCIATED COMORBIDITY 
PROGRESSION 
2.2.1 Introduction to microRNA 
MicroRNAs or miRNAs are small nucleotide of highly conserved non-coding RNA molecules 
that in normal cells maintain various necessary cellular processes.  Dysregulation of these 
miRNAs can therefore lead to dire consequences (Kasinski & Slack, 2011). More than three 
percent of all the genes in an individual codes for miRNA which in turn regulates the expression 
of thousands of target mRNAs (O'Driscoll, 2006).  MicroRNAs, through regulation of mRNAs 
are involved in development, stem cell regulation and human diseases. The association between 
miRNAs and their target mRNA is extremely diverse and complex as a single miRNA has the 
potential to regulate multiple mRNA, and on the other had multiple miRNA can all regulate a 
single mRNA as well (Yi & Fuchs, 2011).  
2.2.2 Function and Processing of microRNA 
MicroRNAs were previously thought to be unnecessary bits of RNA floating around with no 
necessary function, but it was discovered that these small, about 18-25 nucleotides, clusters of 
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non-coding RNA actually play a major role in regulating gene expression (Ranganathan & 
Sivasankar, 2014).  Mature miRNA form protein complexes called miRISC-miRNA-induced 
silencing complex, to bind to target mRNA to either inhibit translation of the mRNA or degrade 
the mRNA (Williams, 2008).  
2.2.3 Relationship between miRNA and Disease 
There is dysregulation seen in miRNA in cancer cells and various damaged tissues, therefore 
miRNA is believed to play a functional role in the development of diseases. It is believed that 
circulating miRNA, (“miRNA that is seen in cell-free serum”) can be used to identify individuals 
that are diseased for those that are not (Weiland, Gao, Zhou, & Mi, 2012). Though there is still 
relatively little known about the actual function of miRNA, because of their roles in clinical 
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3.0  THESIS AIMS 
Host cellular gene expression (transcriptome) profile in response to pathogen interaction is 
directly correlated with disease patterns. Gene expression in response to pathogens is regulated 
by host genetics, epigenetics and external factors. We hypothesize that behavioral factors,  such 
as smoking of tobacco, drinking of alcohol, and illicit drug usage influence host cellular gene 
expression in part by microRNA regulation. This differential regulation in turn may accelerate 
HIV-1 disease progression and HIV-1 associated co-morbidities such as CVD (cardio-vascular 
disease), COPD (constrictive obstructive pulmonary disease) and HAND.  
Aim #1 - To assess whether smoking, alcohol consumption and marijuana use have any 
role in miRNA expression in the context of HIV-1 infection and neurocognitive 
disorder/dementia 
A) MicroRNA profiling in PBMCs of uninfected controls and HIV-1 infected subjects with 
and without dementia 
B) Determine the effect of behavioral factors on miRNA expression and dysregulation 
 
Aim #2- To identify the biological pathways associated with differentially regulated 
miRNAs in HIV-1 infected subjects with or without dementia 
A) Computational analyses to predict the potential mRNA target genes 
B) Identification of biological pathways regulated by the predicted mRNAs 
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4.0  MATERIALS AND METHODS 
4.1 SAMPLE SELECTION 
Samples used in this study were acquired from the Multicenter AIDS Cohort Study (MACS). 
The samples were divided, into three categories based on their HIV-1 status and the presence of 
dementia, in order to carry out a cross-sectional study. The behavioral habits and antiretroviral 
use information for each individuals was also provided by the MACS. The samples were 
categorized as uninfected seronegative group, 1A (N=32), HIV-1 positive dementia negative 2D, 
(N=20), and HIV-1 positive dementia positive 2E, (N=26). HIV-1 positive individuals were 
grouped into dementia negative and dementia positive based on a comprehensive exam 
performed in the MACS clinics. The individuals are placed in the dementia category if they 
consistently (more than 3 times) fail the cognitive exams as well as based on the brain pathology, 
if the samples were taken from deceased individuals. Peripheral blood mononuclear cells were 
obtained from each patient, from which RNA was extracted. The extracted RNA was then 
converted to cDNA, which then profiled for various miRNA using the TaqMan Human 
MicroRNA Array A and the TaqMan Array Human MicroRNA B card. The lists of miRNA 
obtained from these arrays were used in the computation analysis; to detect miRNA that could 
potentially altered by behavioral factors associated with the development of HAND.  Details of 
the subjects including age, collection date, CD4 count, viral load, behavioral habits and antiviral 
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use are listed in Table 1, 2 and 3. In tables 1, 2 and 3, individuals are placed in the used smoking 
category if they have 30 or more pack years. A pack year is defined as twenty cigarettes smoked 
every day for one year according to the National Cancer Institute. Individuals are placed in the 
used alcohol category if they are defined as being alcoholics by the FDA, hat is if they have 
thirteen or more drinks per week. Individuals are placed in the marijuana category if they have 
ever used marijuana. 
Table 1: Details of Study Subjects (Uninfected Control Group) 
ID Age CD4 on collection 
day 
Smoke Alcohol Marijuana 
1A 50 790 2 1 1 
2A 51 2194 2 2 2 
3A 77 489 1 2 1 
4A 72 530 1 1 1 
5A 58 568 2 1 1 
6A 52 993 2 1 1 
7A 56 488 2 1 1 
8A 52 733 2 1 1 
9A 50 944 1 1 1 
10A 64 879 2 1 1 
11A 54 644 1 1 1 
12A 55 584 2 1 1 
13A 56 385 2 2 2 
14A 55 889 2 2 2 
15A 51 885 1 1 2 
16A 53 702 1 2 2 
17A 57 537 1 1 1 
18A 60 1019 1 1 1 
19A 49 589 1 1 1 
20A 46 918 2 1 1 
21A 49 685 2 2 2 
22A 42 841 2 2 2 
23A 38 1074 2 1 1 
24A 42 1634 1 1 2 
25A 38 545 1 1 1 
26A 28 1178 2 2 2 
27A 36 852 2 1 1 
28A 36 789 2 1 1 
29A 30 732 1 2 2 
30A 28 857 2 2 2 
12 
Table 1 Continued 
31A 43 1106 1 2 1 
32A 33 886 2 2 1 
               Legend 
 1- Did not use 
 2- Used  
The above table represents the number of individuals categorized as HIV-1 positive/dementia 
negative, their age, date of sample collection, CD 4 count, viral load, antiviral use and lists their 
behavioral exposures. 
Table 2: Details of Study Subjects (HIV-1 Positive Dementia Negative Group) 
MY 
ID 
Age Collection 
Date 
CD4 
Count 
Viral 
Load 
Smoke Alcohol Marijuana Antiviral 
1D 33 5/27/92 310 127376 2 1 2 1 
2D 2/8/91 100 111314 2 1 1 2 
3D 35 11/5/90 38 167261 2 1 1 1 
4D 42 3/28/01 232 252692 1 1 1 2 
5D 50 4/9/96 120 297672 1 1 1 2 
6D 10/18/88 336 161325 2 2 2 2 
7D 39 2/8/96 188 201158 1 2 1 1 
8D 11/3/87 272 50530 1 1 1 2 
9D 5/14/94 215 184411 1 2 1 2 
10D 1/13/87 120 370999 2 2 1 1 
11D 51 5/2/96 136 561627 1 2 1 2 
12D 28 5/22/92 234 46053 1 2 1 1 
13D 47 11/12/94 151 146580 2 2 1 1 
14D 36 4/23/99 312 71580 2 1 1 2 
15D 40 11/13/87 351 116293 1 1 1 1 
16D 39 7/17/95 96 47310 1 1 2 2 
17D 37 4/14/99 378 289528 2 1 1 2 
18D 37 9/29/08 222 96534 2 1 2 2 
19D 43 2/6/11 179 79454 1 1 1 2 
20D 12/22/93 36 2 1 1 2 
Legend 
1- Did not use 
2- Used 
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The above table represents the number of individuals categorized as HIV-1 positive/dementia 
negative, their age, date of sample collection, CD 4 count, viral load, antiviral use and lists their 
behavioral exposures. 
 
Table 3: Details of Study Subjects (HIV-1 Positive Dementia Positive Group) 
MY 
ID 
Age Collection 
date 
CD4 
count 
Viral 
Load 
Smoke Alcohol Marijuana Antiviral 
1E 45 09/18/03 636 261140 2 1 2 2 
2E 37 05/07/89 601 11888 2 2 1 1 
3E 33 01/04/95 39 470923 2 2 2 1 
4E 36 05/15/95 205 . 2 2 2 1 
5E 40 11/15/90 418 195000 2 2 2 1 
6E 42 11/06/94 41 277132 2 2 2 1 
7E 49 06/23/93 271 . 2 2 2 1 
8E 43 08/01/93 696 18991 2 2 2 1 
9E 46 10/03/93 22 288518 1 2 1 1 
10E 42 08/03/92 33 28120 2 2 2 1 
11E 50 02/13/92 209 103947 2 2 2 1 
12E 48 05/20/96 416 313669 1 1 2 2 
13E 52 06/20/02 179 63386 2 2 1 2 
14E 40 02/09/93 416 . 1 2 2 1 
15E  9/21/99 337 76521 2 2 2 2 
16E 49 10/19/92 336 161325 2 2 2 1 
17E  4/6/99 162 198196 2 1 2 2 
18E 39 07/21/93 451 11595 2 2 1 1 
19E  6/29/07 219 336300 2 1 1 2 
20E  4/12/07 246 47083 2 1 1 2 
21E 34 07/24/92 65 280987 1 1 1 2 
22E 36 08/07/89 265 791689 2 2 2 1 
23E 34 05/15/92 446 116040 2 2 1 1 
24E 38 06/22/92 197 80600 1 2 1 1 
25E 45 09/28/89 267 681894 2 1 1 1 
26E 47 09/30/93 151 95883 2 1 1 2 
Legend 
1- Did not use 
2- Used 
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The above table represents the number of individuals categorized as HIV-1 positive/dementia 
positive, their age, date of sample collection, CD 4 count, viral load, antiviral use and lists their 
behavioral exposures. 
4.2 CATEGORIZATION OF SAMPLES  
Once the individuals were separated based on their HIV-1 status, they were further grouped 
based on their behavioral habits. Subjects were placed in the tobacco smoking category, 
depending on how long an individual smoked and whether they were heavy smokes, or 
mild/non-smokers. In the alcohol consumption category, the patients were stratified based as 
alcoholic who had thirteen or more drinks a week, or non-alcoholic who had less than three 
drinks a week. In the illicit drug use, the individuals were grouped based on whether an 
individual used or did not use marijuana. The individuals were then finally grouped based on 
whether they were on antiretroviral therapy or not. 
4.3 COMPUTATIONAL ANALYSIS 
Statminer, a bio-informatics tool, was used to identify genes that showed significant differential 
expression/integration of biological pathways by comparing the miRNA’s of controls vs. HIV-1 
positive/dementia negative vs. HIV-1 positive/dementia positive. 
After the individuals were separated based on their behavioral habits, the individuals’ 
miRNA were first intra-compared (comparison within a group, heavy smokers in uninfected 
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controls vs mild/non- smokers in uninfected controls, etc.) to recognize the miRNA that was 
commonly regulated within each category. Then the miRNA was inter-compared, for example 
individuals who were heavy smokers in the uninfected controls were compared with the 
individuals that were heavy smokers in HIV-1 positive group with and without dementia, etc. to 
identify the miRNA that were commonly effected in heavy smokers, in all three categories.  
Target Scan, an online software program provided by MIT, was used for predication of 
mRNA target genes. This software is effective in providing a list of predicated gene targets for a 
particular miRNA. These gene target lists were then analyzed using another software that 
predicts the most probable pathways affected by the target genes. 
Integrated pathway analysis (IPA), an online-based tool used to perform functional 
analysis was used to construct canonical pathways that are possibly affected by the regulated 
miRNA. These pathways help us visualize the different functions that are potentially affected by 
the miRNA. 
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5.0  RESULTS 
5.1 AIM #1 - TO ASSESS WHETHER SMOKING, ALCOHOL CONSUMPTION 
AND POT USE HAVE ANY ROLE IN MIRNA EXPRESSION IN THE CONTEXT OF 
HIV-1 ASSOCIATED NEUROCOGNITIVE DISORDER/DEMENTIA 
5.1.1 MicroRNA profiling in PBMCs of uninfected controls and HIV-1 infected subjects 
with and without dementia 
To examine the effects of the behavioral exposures on miRNA profiles in the uninfected 
controls, HIV-1+/dementia- and HIV-1+/dementia+, we isolated miRNA from PBMC’s and 
profiled it using Taqman assay using four endogenous controls.  
The miRNA profiling consisted of running two microfluidic cards per sample for the 
combined effect of the ability to detect 768 miRNA and 12 controls.  The samples, where the 
endogenous controls exceeded Ct value of 25 were eliminated. Our endogenous control analyses 
indicate that the Ct values for all our samples range from 15-22 and none of them are more than 
25. 
Initially miRNA within the groups that is the miRNA obtained for the uninfected control 
group in smoking was compared to the uninfected control group non-smoking. The same was 
assessed within the HIV-1 positive/dementia negatives groups and the HIV-1positive/dementia 
positive groups, using all three behavioral factors. By comparing the resulting miRNA lists from 
 17 
the intra-comparisons, inter- comparison (between the categories) was done to find commonly 
regulated miRNA.   Table 2 shows the number or subjects in each category. 
Table 4: Number of Subjects in Each Category Separated by Behavioral Exposures 
 Smoking Alcohol Marijuana All three Substances 
 Yes No Yes No Yes No Yes No 
Uninfected Controls 
(n=32) 
19 13 12 20 11 21 7 25 
HIV-1 positive/dementia 
negative (n=20) 
10 10 7 13 4 16 1 19 
HIV-1 positive/dementia 
positive (n=26) 
21 5 18 8 9 17 11 15 
 
Differentially regulated miRNAs between these groups were analyzed using two different 
software packages using appropriate settings required for each program to maximize the 
confidence.  The first program used was Realtime Statminer, a bioinformatics program which 
analyzes significantly differentially regulated miRNA within and between these groups. Results 
indicate that the behavioral exposures, differentially regulated the expression of several 
miRNAs, signified by p-value of less than 0.05 and fold change calculated based on 
normalization with endogenous control, U6 snRNA/MammU6. Figures 2, 3, 4 illustrate the 
number miRNA regulated in each category as well as the number miRNAs that were commonly 
regulated. Tables 3, 4, 5 exhibit the miRNA that were found to be commonly regulated in 
selected two categories.  
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The Venn diagram displays the number and overlap of significantly differentially expressed 
miRNA (no FDR adjustment, p<0.05) among the HIV-positive/dementia negative and HIV-
positive/ dementia positive groups relative to the Uninfected controls and within the 
infected groups.  MiRNAs represent those miRNAs that are found to be significantly 
differentially regulated.  
Figure 1: Venn Diagrams Illustrating Number of Commonly Regulated MiRNA in Smoking
Venn diagrams illustrating the number of miRNA significantly regulated due to smoking in each 
category as well as the number of miRNA that are commonly regulated in both categories. 
Table 5: MicroRNA Regulated by Smoking in Controls and HIV-1 Positive Dementia Negative 
Uninfected Controls HIV-1 positive/dementia 
negative 
MicroRNA Fold Change P-Value Fold Change P-Value 
hsa-miR-152 7.5407 0.0122 2.6747 0.0193 
hsa-miR-629 -2.3568 0.0330 4.1165 0.0103 
hsa-miR-874 5.3286 0.0133 19.2739 0.0250 
hsa-miR-148 3.4703 0.0328 2.9295 0.0183 
The above table lists the miRNA that were found to be differentially regulated due to smoking in 
uninfected controls and HIV-1 positive/dementia negative individuals. The fold change indicates the 
quantity changes of expression of the test group by expression of the control group, a positive number 
specifies up-regulation, and a negative number specifies down-regulation. The p-value indicates the 
significance of the fold change (based on 0.05 significance) 
The above table indicates that there is significant miRNA dysregulation due to smoking. For 
example, hsa-miR-629 is down regulated in the uninfected controls, whereas, it is significantly 
up-regulated in HIV-1 positive/dementia negative individuals. Hsa-miR-874 is up regulated in 
both categories, but in HIV-1 positive/dementia negative individuals this miRNA has a much 
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higher fold change, compared to control group. These dysregulations could be due to the 
smoking of tobacco, due to the HIV-1 infection or due to a combination of both.  
The Venn diagram displays the number and overlap of significantly differentially expressed 
miRNA (no FDR adjustment, p<0.05) among the HIV-1 positive/dementia negative and HIV-1 
positive/ dementia positive groups relative to the Uninfected controls and within the infected 
groups.  MiRNAs represent those miRNAs that are found to be significantly differentially 
regulated. 
 Figure 2: Venn Diagrams Illustrating Number of Commonly Regulated MiRNA in Alcohol 
Venn diagrams illustrating the number of miRNA significantly regulated due to alcohol in each 
category as well as the number of miRNA that are commonly regulated in both categories. 
Table 6: MicroRNA Regulated by Alcohol in Controls and HIV-1 Positive Dementia Negative 
Uninfected Controls HIV-1 positive/dementia 
negative 
MicroRNA Fold Change P-Value Fold Change P-Value 
hsa-miR-125a-3p -4.4821 0.013 -8.2404 0.0311 
hsa-miR-1304 26.9748 0.000 37.3787 0.0384 
hsa-miR-455-3p 8.1547 0.0032 -13.5234 0.0444 
hsa-miR-147 13.4689 0.0040 8.5758 0.0296 
hsa-miR-556 -33.4100 0.0166 7.7604 0.0194 
The above table lists the miRNA that are found to be differentially regulated due to alcohol in uninfected 
controls and HIV-1 positive/dementia negative individuals. The fold change indicates the quantity changes 
of expression of the test group by expression of the control group, a positive number specifies up-
regulation, and a negative number specifies down-regulation. The p-value indicates the significance of the 
fold change (based on 0.05 significance) 
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In Table 6, the miRNA deregulated by alcohol are listed and here we observed differential 
regulation of these miRNA when comparing the miRNAs fold change and significant p-value in 
the controls vs HIV-1 positive/dementia negative subjects. Though all the miRNA listed have 
differences in their quantity and regulation, the two miRNA that are most significantly regulated 
are hsa-miR-455-3p and hsa-miR-556,  both of them are inversely correlated  in controls 
compared to HIV-1+/dementia- individuals. In this behavioral exposure as well we cannot 
explicitly say whether the alcohol or the virus is causing the disparities, though disparity is 
observed. 
Table 7: MicroRNA Regulated by Alcohol in Controls and HIV-1 Positive Dementia Positive 
 Uninfected Control HIV-1 positive/dementia 
positive 
MicroRNA Fold Change P-Value Fold Change P-Value 
hsa-miR-518 28.2518 0.0039 -97.1187 0.0221 
The above table lists the miRNA that are found to be differentially regulated due to alcohol in uninfected 
controls and HIV-1 positive/dementia positive individuals. The fold change indicates the quantity changes 
of expression of the test group by expression of the control group, a positive number specifies up-
regulation, and a negative number specifies down-regulation. The p-value indicates the significance of the 
fold change (based on p< 0.05) 
 
The above table highlights one of the largest disparities, the miRNA is up-regulated in the 
controls but is extremely down-regulated in HIV-1 positive/dementia positive individuals. This 
disparity could be caused by one of four conditions, it could be due to the virus; it could be due 
to the alcohol; it could be due to the dementia, or it could be due to any combination of the three. 
 
 
 
 
21 
Table 8: MicroRNA Regulated by Marijuana in HIV-1 Positive Dementia Negative and HIV-1 
Positive Dementia Positive 
HIV-1 positive/dementia 
negative 
HIV-1 positive/dementia 
positive 
MicroRNA Fold Change P-Value Fold Change P-Value 
hsa-miR-218-1# 12988.3322 0.0019 -6.2417 0.0213 
hsa-miR-497 21.7973 0.0007 -20.1807 0.0009 
The above table lists the miRNA that are found to be differentially regulated due to alcohol in HIV-1 
positive/ dementia negative individuals and HIV-1 positive/dementia positive individuals. The fold change 
indicates the quantity changes of expression of the test group by expression of the control group, a 
positive number specifies up-regulation, and a negative number specifies down-regulation. The p-value 
indicates the significance of the fold change (based on 0.05 significance) 
The above table indicates that miRNA that are dysregulated due to marijuana use in HIV-1 
positive individuals with and without dementia. This table shows that hsa-miR-218-1# was 
present in extremely large quantities and up-regulated in HIV-1 positive/dementia negative 
individuals but was down regulated in HIV-1 positive/dementia positive individuals. This 
extremely large discrepancy could have been due to a technical error on part of the software 
program used, but it could also be that this miRNA is up-regulated and is present in large 
quantities in the HIV-1 positive/dementia negative individuals. 
The Venn diagram displays the number and overlap of significantly differentially expressed miRNA (no 
FDR adjustment, p<0.05) among the HIV-positive/dementia negative and HIV-positive/ dementia positive 
groups relative to the Uninfected controls and within the infected groups.  MiRNAs represent those 
miRNAs that are found to be significantly differentially regulated by RealTime StatMiner.  
Figure 3: Venn Diagrams Illustrating Number of Commonly Regulated MiRNA in Marijuana
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Venn diagrams illustrating the number of miRNAs significantly regulated due to pot use in each 
category as well as the number of miRNAs that are commonly regulated in both categories. 
Table 9: MicroRNA Regulated by Marijuana in Controls and HIV-1 Positive Dementia Negative 
Uninfected Controls HIV-1 positive/dementia 
negative 
MicroRNA Fold Change P-Value Fold Change P-Value 
hsa-miR-548 8.0224 0.0088 10.6886 0.0445 
The above table lists the miRNA that are found to be differentially regulated due to pot use in uninfected 
controls and HIV-1 positive/dementia positive individuals. The fold change indicates the quantity changes 
of expression of the test group by expression of the control group, a positive number specifies up-
regulation, and a negative number specifies down-regulation. The p-value indicates the significance of the 
fold change (based on 0.05 significance) 
The above table shows that the miRNA hsa-miR-548 was up-regulated in both the uninfected 
controls as well as the HIV-1 positive/ dementia negative individuals, thought there was a 
slightly larger quantity of the miRNA in the latter. 
Table 10: MicroRNA Regulated by Marijuana in HIV-1 Positive Dementia Negative and HIV-1 
Positive Dementia Positive 
HIV-1 positive/dementia 
negative 
HIV-1 positive/dementia 
positive 
MicroRNA Fold Change P-Value Fold Change P-Value 
hsa-miR-558 22.1775 0.0043 -6.1437 0.0090 
The above table lists the miRNA that are found to be differentially regulated due to pot use in HIV-1 
positive/dementia negative and HIV-1 positive/dementia positive individuals. The fold change indicates 
the quantity changes of expression of the test group by expression of the control group, a positive 
number specifies up-regulation, and a negative number specifies down-regulation. The p-value indicates 
the significance of the fold change (based on 0.05 significance) 
The above table indicates that hsa-miR-558 is differentially regulated in individuals with HIV-1 
and with or without dementia. In HIV-1 positive/dementia negative individuals the miRNA is 
present 22 times higher fold than the endogenous miRNA and is being up-regulated, whereas, in 
HIV-1 positive/dementia positive individuals this miRNA has decreased in quantity by 6 fold 
and is being down-regulated. 
 23 
5.2 AIM #2- IDENTIFY THE BIOLOGICAL PATHWAYS ASSOCIATED WITH 
DIFFERENTIALLY REGULATED MIRNAS IN HIV-1 INFECTED SUBJECTS WITH 
OR WITHOUT DEMENTIA 
5.2.1 Computational analyses to predict possible mRNA target genes 
Once we had identified the miRNA that were being differentially regulated due to the behavioral 
exposures, we next conducted an analysis to predict the most probable mRNA gene targets, and 
their downstream pathways. The program used to predict possible mRNA target genes was 
Target Scan. The miRNA (listed in Tables 3,4,5) obtained through the cross sectional study were 
input into an online database called Target Scan, which produced a list of possible target genes. 
These lists of target genes were then analyzed using Integrated Pathway Analysis (IPA), an 
analytical software program, which generates images of affected genes and their upstream and 
downstram pathways. It was also used to create canonical pathways, which show the 
downstream effects of the genes being regulated by the miRNAs. Figures 5, 6, and 7 represent 
the potential pathways affected due to several of the listed miRNA. Figures 8, 9, and 10 illustrate 
the network of genes predicted to be regulated by several of the listed miRNAs.  
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Figure 4: Network Showcasing Pathways Affected by hsa-miR-152 
The above figure represents the top eight predicted pathways that miR-152 is most likely 
affecting according to Integrated Pathway Analysis. Has-miR-152 was found to be commonly 
regulated due to smoking in both uninfected controls and HIV-1 positive/dementia negative 
individuals. The Neuregulin Signaling is responsible for many various functions including 
development of the nervous system, Schwann cell and oligodendrocyte differentiation, and 
formation of neuromuscular synapses. 
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Figure 5: Network Showcasing Pathways Affected by hsa-miR-218 
 
Figure 6: Network Showcasing Pathways Affected by hsa-miR-497 
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Figure 7: Genes and Their Probable Functions Affected by hsa-miR-629 
 
The above figure represents the most probable genes affected due to miR-629 and the diseases 
states they regulate. Hsa-miR-629 was commonly regulated in smoking in both uninfected 
controls and HIV-1 positive/dementia negative. 
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Figure 8: Genes and Their Probable Functions Affected by hsa-miR-558 
 
Figure 9: Genes and Their Probable Functions Affected by hsa-miR-645 
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6.0  DISCUSSION 
The first case of HIV-1 reported in the United States was in 1981, and since then 75 million 
cases globally have been reported. Currently there are 35 million people living with HIV-1 
globally. The incidence of HIV-1 has decreased from 3.2 million in 2010 to 2.5 million in 2013, 
but the prevalence has been increasing steadily, mainly due to availability of advanced medical 
technologies. Now the aging HIV-1 positive population has bought with it new and complex 
challenges to the issue of treating an individual with AIDS. We now face another major problem 
in our quest to stamp out HIV-1, preventing, diagnosing and treating the co-morbidities 
associated with HIV-1, many of which result in poorer outcomes due to the virus then in those 
who do not have HIV-1. 
The solution is, being able to recognize that an individual is more prone to develop a 
particular co-morbidity and prevent it by modifying their lifestyles and medication. This 
approach is far more efficient and effective then treating the ailment. 
Several of the miRNA that are found to be deregulated by the behavioral factors, play a 
role in cognitive processing. Hsa-miR-152 and hsa-miR-148a are both miRNA that were 
deregulated by smoking in uninfected controls and HIV-1 positive/dementia negative 
individuals. These two miRNA are significantly involved in neuregulin signaling, and 
neuregulins are proteins that have been shown to have diverse functions in the development of 
the nervous system.  
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6.1 FUTURE DIRECTION 
In order to identify the actual deregulating factor of these miRNA, the next step is to find out if 
the behavioral factor, the virus or a combination of both is the causative factor.  A major problem 
exists in trying to separate these exposures into individual factors and see their individual effect 
on the miRNA expression. One possible approach is by performing a multivariate analysis, that 
involves observation and analysis of more than one statistical outcome variable at a time.  
6.2 PUBLIC HEATH SIGNIFICANCE 
Our study on the effect of behavioral exposures on miRNA deregulation has significant public 
health relevance. By continuing with this line of study, it is possible to eventually create miRNA 
biomarkers that would foretell if an individual with certain behavioral exposures would be prone 
to develop HIV-1 associated neurocognitive disorders. Additionally, these biomarkers could be 
used not only in prevention and diagnosis of possible HIV associated co-morbidities but also to 
aid in the determination of the infected individuals’ ability to respond to antiviral treatment as 
well as creating better treatment regimes.  
6.3 LIMITATIONS 
We faced certain restrictions as we conducted our study. The major limitation being we are using 
miRNA obtained from PBMC’s to observe changes in the brain. We acknowledge this limitation, 
but as we are not able to obtain brain tissue samples we are forced to use deductive reasoning to 
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prove our hypothesis. Our next obstacle is that our sample sizes are small, as we did not have 
accurate information on their cognitive impairment or dementia status on all subjects. Due to the 
small sample sizes the values calculated do not fully represent the accurate assessment between 
miRNA regulation in relation to behavioral factors and HAND. Next the variables (behavioral 
exposures) could not be calculated individually as there was insufficient data and a very small 
sample size to do an analysis on individuals who only smoked or who only consumed alcohol in 
each of the established categories (uninfected controls, HIV-1 positive with and without 
dementia). Another future goal of this study, would be to identify individuals in each category 
who only have one behavioral exposure, only smoking of tobacco (more than 30 pack years) or 
only consumption of alcohol (thirteen or more drinks per week). With a larger sample size we 
would be able to calculate a more accurate measure of the miRNAs that are being regulated 
either independently by HAND or in conjunction with behavioral factors. Lastly the data 
assimilated on the HIV-1 positive/dementia negative individuals is subject to change as the 
MACS evaluation of dementia has changed over the years the data was collected. 
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APPENDIX 
LIST OF REGULATED MiRNA 
MiRNA Regulated in Uninfected Controls due to Smoking 
miRNA Fold Change P-value 
hsa-let-7a 2.7331 0.0472 
hsa-miR-105 -2.9579 0.0438 
hsa-miR-106b 7.1113 0.0146 
hsa-miR-124# -22.8650 0.0000 
hsa-miR-1269 -27.0344 0.0001 
hsa-miR-128 4.9951 0.0414 
hsa-miR-130b 3.3704 0.0393 
hsa-miR-138-2# -8.0780 0.0130 
hsa-miR-148a 3.4703 0.0328 
hsa-miR-152 7.5407 0.0122 
hsa-miR-154 7.1934 0.0059 
hsa-miR-15b 4.2456 0.0383 
hsa-miR-181c 5.9955 0.0056 
hsa-miR-181c# 4.2804 0.0407 
hsa-miR-182# 34.5823 0.0432 
hsa-miR-1826 -33.4262 0.0111 
hsa-miR-185 6.0984 0.0325 
hsa-miR-187 -7.7124 0.0069 
hsa-miR-18a 5.6232 0.0308 
hsa-miR-18a# -2.5769 0.0440 
hsa-miR-18b 4.3523 0.0424 
hsa-miR-191# -3.4416 0.0411 
hsa-miR-193a-5p 9.9696 0.0027 
hsa-miR-194 6.0767 0.0220 
hsa-miR-200b# -11.0050 0.0007 
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hsa-miR-202# -5.4450 0.0074 
hsa-miR-203 4.3270 0.0349 
hsa-miR-20b# -18.4465 0.0135 
hsa-miR-21 3.0545 0.0353 
hsa-miR-21# 4.0024 0.0499 
hsa-miR-213 5.1263 0.0381 
hsa-miR-214 -7.2844 0.0234 
hsa-miR-219-1-3p -7.2195 0.0064 
hsa-miR-219-2-3p -5.7948 0.0424 
hsa-miR-22 11.3960 0.0048 
hsa-miR-220b -6.0289 0.0299 
hsa-miR-220c 15.1435 0.0200 
hsa-miR-23b 3.4094 0.0499 
hsa-miR-27a 3.5403 0.0418 
hsa-miR-27b 4.0904 0.0406 
hsa-miR-28-5p 9.3725 0.0046 
hsa-miR-298 -19.7476 0.0001 
hsa-miR-299-3p -161.6296 0.0136 
hsa-miR-29b 10.6408 0.0039 
hsa-miR-302b# 5.1978 0.0393 
hsa-miR-30d# 6.2176 0.0035 
hsa-miR-32 6.2167 0.0033 
hsa-miR-324-5p 6.0227 0.0299 
hsa-miR-325 -29.5116 0.0042 
hsa-miR-337-5p 5.9091 0.0077 
hsa-miR-346 -8.1868 0.0190 
hsa-miR-361-5p 7.6461 0.0031 
hsa-miR-362-5p 7.8214 0.0101 
hsa-miR-369-5p 8.4129 0.0018 
hsa-miR-376c 3.8910 0.0107 
hsa-miR-433 6.9599 0.0121 
hsa-miR-491-3p 9.0747 0.0103 
hsa-miR-494 6.0520 0.0408 
hsa-miR-499-3p 7.9450 0.0218 
hsa-miR-502-3p 3.4724 0.0454 
hsa-miR-508-3p 7.0682 0.0468 
hsa-miR-519b-3p -33.5926 0.0383 
hsa-miR-532-3p 5.1133 0.0294 
hsa-miR-532-5p 4.3246 0.0276 
hsa-miR-551b -30.8829 0.0002 
hsa-miR-556-5p 24.0502 0.0157 
hsa-miR-564 4.7380 0.0234 
hsa-miR-620 -14.5837 0.0010 
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hsa-miR-628-3p -2.1006 0.0285 
hsa-miR-629 -2.3568 0.0330 
hsa-miR-655 4.4654 0.0090 
hsa-miR-874 5.3286 0.0133 
hsa-miR-922 -3.9439 0.0061 
hsa-miR-98 4.9446 0.0164 
 
MiRNA Regulated in HIV-1 Positive Dementia Negative due to Smoking 
miRNA Fold Change P-value 
hsa-let-7g# 9.5690 0.0063 
hsa-miR-1245 -42801.7847 0.0119 
hsa-miR-1263 38.5143 0.0026 
hsa-miR-1283 15.6353 0.0396 
hsa-miR-1284 -1093045.0470 0.0015 
hsa-miR-146a# 16.5449 0.0019 
hsa-miR-148b# 2.9295 0.0183 
hsa-miR-152 2.6747 0.0193 
hsa-miR-204 15.1371 0.0057 
hsa-miR-221# 6.2653 0.0407 
hsa-miR-301b 3.5178 0.0357 
hsa-miR-302d 7.5929 0.0224 
hsa-miR-331-5p 3.6557 0.0488 
hsa-miR-379 3.4224 0.0386 
hsa-miR-384 13.7745 0.0101 
hsa-miR-455-3p -9.4582 0.0190 
hsa-miR-503 7.7328 0.0336 
hsa-miR-513-5p 8.1154 0.0204 
hsa-miR-517b 9.3679 0.0487 
hsa-miR-517c 22.7991 0.0227 
hsa-miR-518a-5p -9.6833 0.0096 
hsa-miR-519e# -77.8612 0.0151 
hsa-miR-545# 3.6892 0.0439 
hsa-miR-548J 5.2669 0.0322 
hsa-miR-562 -12.5317 0.0241 
hsa-miR-566 18.8969 0.0389 
hsa-miR-607 6.5434 0.0346 
hsa-miR-608 5.0932 0.0178 
hsa-miR-614 6.8475 0.0295 
hsa-miR-617 6.3746 0.0208 
hsa-miR-621 29.2438 0.0154 
hsa-miR-625 2.2753 0.0408 
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hsa-miR-629 4.1165 0.0103 
hsa-miR-630 3.8683 0.0419 
hsa-miR-634 3.6298 0.0439 
hsa-miR-658 -411779.5048 0.0329 
hsa-miR-672 4.1666 0.0324 
hsa-miR-874 19.2739 0.0250 
hsa-miR-935 11.0274 0.0185 
hsa-miR-937 8.9544 0.0064 
 
MiRNA Regulated in HIV-1 Positive Dementia Positive due to Smoking 
miRNA Fold Change P-value 
hsa-miR-1200 363.2536 0.0433 
hsa-miR-183# -15.7520 0.0027 
hsa-miR-558 -10.0498 0.0025 
hsa-miR-618 -156.1200 0.0111 
hsa-miR-649 -7.4997 0.0242 
 
MiRNA Regulated in Uninfected Controls due to Alcohol  
miRNA Fold Change P-value 
hsa-let-7e# -6.2318 0.0191 
hsa-miR-10b# 4.3549 0.0250 
hsa-miR-1236 -21.3139 0.0194 
hsa-miR-124# -8.8110 0.0445 
hsa-miR-125a-3p -4.4821 0.0319 
hsa-miR-1294 7.2144 0.0029 
hsa-miR-1304 26.9748 0.0000 
hsa-miR-143# 147.9160 0.0026 
hsa-miR-147 13.4689 0.0040 
hsa-miR-154 -8.2442 0.0298 
hsa-miR-200c# 4.3298 0.0413 
hsa-miR-213 4.9903 0.0447 
hsa-miR-219-1-3p -9.5618 0.0123 
hsa-miR-220 4.9231 0.0201 
hsa-miR-23b 4.4617 0.0198 
hsa-miR-298 -7.9247 0.0241 
hsa-miR-331-3p 12.3765 0.0318 
hsa-miR-369-3p 7.5212 0.0062 
hsa-miR-455-3p 8.1547 0.0032 
hsa-miR-515-5p 5.1602 0.0099 
hsa-miR-518a-3p 28.2518 0.0039 
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hsa-miR-548c-3p 11.6331 0.0003 
hsa-miR-551b -20.0687 0.0316 
hsa-miR-556-5p -33.4100 0.0166 
hsa-miR-616 4.4275 0.0484 
hsa-miR-665 -11.8406 0.0254 
hsa-miR-924 9.0003 0.0106 
 
MiRNA Regulated in HIV-1 Positive Dementia Negative due to Alcohol  
miRNA Fold Change P-value 
hsa-miR-1 -31.2739 0.0355 
hsa-miR-1206 -77.4577 0.0374 
hsa-miR-1245 670457.2010 0.0004 
hsa-miR-125a-3p -8.2404 0.0311 
hsa-miR-125b-1# 11.0038 0.0219 
hsa-miR-1284 168783.6318 0.0089 
hsa-miR-1286 624.4479 0.0125 
hsa-miR-1288 1904.8377 0.0118 
hsa-miR-1293 25.2395 0.0160 
hsa-miR-1304 37.3787 0.0384 
hsa-miR-146a# 8.5758 0.0357 
hsa-miR-147b 8.4551 0.0296 
hsa-miR-181c# 4.4296 0.0314 
hsa-miR-186# 9.2406 0.0231 
hsa-miR-218-1# 12988.3322 0.0019 
hsa-miR-24-1# 8.1806 0.0176 
hsa-miR-302a 5.1852 0.0253 
hsa-miR-30c-2# 203694.0965 0.0017 
hsa-miR-338-3p 8.2353 0.0295 
hsa-miR-455-3p -13.5234 0.0444 
hsa-miR-497 21.7973 0.0007 
hsa-miR-499-5p -65.0177 0.0216 
hsa-miR-513C 10.4754 0.0064 
hsa-miR-519e# 146.8242 0.0057 
hsa-miR-556-3p 7.7604 0.0194 
hsa-miR-562 24.4164 0.0078 
hsa-miR-621 32.6504 0.0009 
hsa-miR-640 6.5634 0.0206 
hsa-miR-658 9463409.1539 0.0019 
 
MiRNA Regulated in HIV-1 Positive Dementia Positive due to Alcohol  
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miRNA Fold Change P-value 
hsa-miR-1200 -172.7587 0.0006 
hsa-miR-148a# -77.5513 0.0064 
hsa-miR-218-1# -6.2417 0.0213 
hsa-miR-296-3p -7.8476 0.0384 
hsa-miR-410 -4.0707 0.0475 
hsa-miR-432# 14.0221 0.0332 
hsa-miR-497 -20.1807 0.0009 
hsa-miR-518f -97.1187 0.0221 
hsa-miR-645 -609.7084 0.0000 
hsa-miR-646 20.1555 0.0277 
hsa-miR-663B 17.9712 0.0003 
hsa-miR-873 -4.9876 0.0403 
 
MiRNA Regulated in Uninfected Controls due to Marijuana 
miRNA Fold Change P-value 
hsa-let-7f -4.1435 0.0297 
hsa-miR-1236 -18.5085 0.0280 
hsa-miR-124# 10.2281 0.0025 
hsa-miR-1294 11.6364 0.0001 
hsa-miR-1304 18.4212 0.0002 
hsa-miR-146a 24.6677 0.0365 
hsa-miR-146a# -16.7871 0.0405 
hsa-miR-182 3.0618 0.0340 
hsa-miR-1826 -36.3647 0.0157 
hsa-miR-298 5.8575 0.0361 
hsa-miR-30c-1# 58.1894 0.0001 
hsa-miR-373 20.7765 0.0110 
hsa-miR-424 4.7848 0.0207 
hsa-miR-455-3p 6.2242 0.0181 
hsa-miR-493 6.4773 0.0170 
hsa-miR-508-3p -9.9381 0.0221 
hsa-miR-515-5p 4.5998 0.0187 
hsa-miR-518a-3p 24.3918 0.0069 
hsa-miR-518d-5p -6.6338 0.0285 
hsa-miR-520D-3P -101.5054 0.0379 
hsa-miR-522 9.1623 0.0374 
hsa-miR-548c-3p 8.0224 0.0088 
hsa-miR-549 993.0585 0.0023 
hsa-miR-551b 0.0488 0.0252 
hsa-miR-556-5p 0.0320 0.0264 
 37 
hsa-miR-638 7.3658 0.0180 
hsa-miR-643 10.6075 0.0106 
hsa-miR-665 -15.8040 0.0050 
hsa-miR-872 -22.6918 0.0290 
hsa-miR-892b 43.1518 0.0056 
hsa-miR-924 9.3221 0.0074 
 
MiRNA Regulated in HIV-1 Positive Dementia Negative due to Marijuana 
miRNA  Fold Change P-value 
has-miR-155 2.0672 0.0417 
hsa-miR-1183 -6.5058 0.0149 
hsa-miR-1225-3P -4.1301 0.0466 
hsa-miR-191 2.3440 0.0205 
hsa-miR-218-1# -338.8942 0.0089 
hsa-miR-219-2-3p 10.5538 0.0075 
hsa-miR-223 2.4377 0.0477 
hsa-miR-302d# -34.8868 0.0037 
hsa-miR-376a 4.3875 0.0380 
hsa-miR-411 5.2922 0.0186 
hsa-miR-488 -17.9644 0.0139 
hsa-miR-490-3p -26.7345 0.0007 
hsa-miR-548L 10.6886 0.0445 
hsa-miR-558 22.1775 0.0043 
hsa-miR-573 -18.1189 0.0454 
hsa-miR-651 9.0292 0.0412 
hsa-miR-935 10.6989 0.0070 
 
MiRNA Regulated in HIV-1 Positive Dementia Positive due to Marijuana 
miRNA Fold Change P-value 
has-miR-1305 349.1311 0.0034 
hsa-miR-101# -4.5587 0.0221 
hsa-miR-1200 -65.4799 0.0082 
hsa-miR-1298 15.1064 0.0110 
hsa-miR-149# 5.3230 0.0293 
hsa-miR-183# -5.4831 0.0249 
hsa-miR-190b 2.6225 0.0427 
hsa-miR-215 3.9364 0.0495 
hsa-miR-483-3p 7.5973 0.0307 
hsa-miR-483-5p 3.4516 0.0351 
hsa-miR-558 -6.1437 0.0090 
 38 
hsa-miR-584 22.9982 0.0263 
hsa-miR-616 0.2886 0.0458 
hsa-miR-631 -5.5190 0.0071 
hsa-miR-645 -193.0356 0.0000 
hsa-miR-934 -7.5912 0.0033 
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